Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of statin dose response in electronic medical records.

Clinical pharmacology and therapeutics - 1 Mar 2014

Wei W-Q, Feng Q, Jiang L, Waitara M S, Iwuchukwu O F, Roden D M, Jiang M, Xu H, Krauss R M, Rotter J I, Nickerson D A, Davis R L, Berg R L, Peissig P L, McCarty C A, Wilke R A, Denny J C

Abstract excerpt

Efforts to define the genetic architecture underlying variable statin response have met with limited success, possibly because previous studies were limited to effect based on a single dose. We leveraged electronic medical records (EMRs) to extract potency (ED50) and efficacy (Emax) of statin dos...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to Electronic Health Records
Share to Heptanoic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipidemias

Share to Pyrroles

Share to Randomized Controlled Trials as Topic

Share to Simvastatin

Source

Open in PubMed Open full text

Identifiers

PMID: 24096969
DOI: 10.1038/clpt.2013.202
PMCID: PMC3944214

Genes

PRDM16

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24096969-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of statin dose response in electronic medical records.PMID 24096969Read ↗

Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use.Semantic proximity Read ↗

Characterization of Low‐Density Lipoprotein Cholesterol‐Lowering Efficacy for Atorvastatin in a Population‐Based DNA BiorepositorySemantic proximity Read ↗

Biobank scale pharmacogenomics informs the genetic underpinnings of simvastatin useSemantic proximity Read ↗

Investigating the genetic factors of medication dosing using biobank-linked drug purchase dataSemantic proximity Read ↗

Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records.Semantic proximity Read ↗

Pharmacogenomics of statin response.Semantic proximity Read ↗

Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug-Gene Interactions for Commonly Used Drugs.Semantic proximity Read ↗

Clinical implications of pharmacogenomics of statin treatmentSemantic proximity Read ↗

<i>LPA</i> and <i>APOE</i> are associated with statin selection in the UK BiobankSemantic proximity Read ↗

Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE's multiethnic population.Semantic proximity Read ↗

Using electronic health records for clinical pharmacology research: Challenges and considerations.Semantic proximity Read ↗

Comparative Analysis of Atorvastatin and Rosuvastatin Side Events and Risk Factors in the UAE Multiethnic Population: Focus on Pharmacogenomic VariantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.